Shares of Shield Therapeutics plc (LON:STX – Get Free Report) traded down 44.5% on Tuesday. The stock traded as low as GBX 2.93 and last traded at GBX 3.05. Approximately 41,407,309 shares traded hands during mid-day trading, an increase of 1,606% from the average daily volume of 2,427,170 shares. The stock had previously closed at GBX 5.50.
Shield Therapeutics Trading Down 4.6%
The stock’s 50 day moving average is GBX 5.19 and its two-hundred day moving average is GBX 6.87. The company has a market capitalization of £35.34 million, a PE ratio of -3.29 and a beta of 1.77. The company has a quick ratio of 2.16, a current ratio of 0.75 and a debt-to-equity ratio of -146.28.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Further Reading
- Five stocks we like better than Shield Therapeutics
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
